Clinical and Experimental Pharmacology and Physiology · 2020 · 15 citations · 28 references
MedicineNephrologyPharmacologyMolecular PharmacologyPharmacodynamicsRenal PathophysiologyEndothelial DysfunctionHypertensive NephropathyRenal DiseaseRenal Molecular PhysiologyRenal PharmacologyRenal Vascular DiseaseHypertensive Renal HemodynamicsPathogenesis Of Hypertensive NephropathyRenal Hemodynamic AlterationsRenal Hemodynamic EffectsRenin-angiotensin System BlockadeRenin-angiotensin System ModulationRenin-angiotensin-aldosterone System ActivationVascular Endothelial Dysfunction
-nitro-L-arginine methyl ester hydrochloride (L-NAME)-induced hypertensive rats were investigated in this study. Male Sprague-Dawley rats were administered L-NAME (40 mg/kg/day), L-NAME plus hesperidin (30 mg/kg/day), and L-NAME plus captopril (2.5 mg/kg/day) for 5 weeks. Hesperidin and captopril significantly prevented L-NAME-induced hypertension, vascular and renal dysfunction, intrarenal artery remodelling, glomerular extracellular matrix accumulation, and renal fibrosis. The preventive treatment with hesperidin and captopril also significantly decreased serum angiotensin-converting enzyme activity and plasma transforming growth factor-β1 (TGF-β1) levels and downregulated angiotensin II receptor type I and TGF-β1 protein expression in the kidneys. In addition, decreased malondialdehyde levels and increased superoxide dismutase activity in the plasma and kidney were observed after co-treatment with hesperidin or captopril. These findings suggest that hesperidin inhibits L-NAME-induced vascular and renal alterations in rats. The possible mechanism may be related to the suppression of the activation of the renin-angiotensin system and expression of TGF-β1, and reduction of oxidative stress.
28
Ching-Fang Wu, Wen‐Chih Chiang, Chun‐Fu Lai et al. · American Journal Of Pathology · 2012 · 247 citations · Full text